关键词: 晚期结直肠癌, 奥沙利铂, 氟尿嘧啶, KRAS突变, 伊立替康

Abstract: 【Abstract】〓Objective〓Some researches found that KRAS mutation advanced colorectal cancer may predict sensitivity to oxaliplatin. This acticle enlarge more samples based on previous research. Objective to investigate which is the better regimen for KRAS mutation advanced colorectal cancer. Methods〓Between 2005 and 2016, 112 advanced colorectal cancer patients with KRAS mutation were retrospectively analyzed. Of them 72 patients received first-line oxaliplatin-based chemotherapy while 40 patients received iriontecan-based chemotherapy. The primary endpoint was overall survival, the secondary endpoints were disease control rates and progression-free survival. Results〓Median overall survival was 24.9 months for oxaliplatin and 26.5 months for iriontecan (P=0.978), with DCR was 69.4% and 62.5%, respectively (χ2=0.561,P=0.454). Median progression-free survival was 8.5 months for oxaliplatin and 8.5 months for iriontecan which had no statistical significance (P=0.412). Conclusion It was demonstrated that oxaliplatin-based chemotherapy and iriontecan-based chemotherapy in the first-line had similar efficacy in patients with KRAS mutation advanced colorectal cancer.

Key words: KRAS mutation, Advanced colorectal cancer, Fluorouracil, Oxaliplatin, Irinotecan